Latest Hotspot

Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions

9 February 2024
3 min read

Sirius Therapeutics disclosed that it initiated dosing with its innovative siRNA therapeutic, SRSD107, targeting the coagulation Factor XI (FXI) in the inaugural participant of a Phase 1 clinical trial conducted in Australia. This trial is focused on investigating SRSD107 for its potential in both preventing and managing thromboembolic conditions.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The biopharmaceutical enterprise has introduced SRSD107 as their second promising agent within the collection of innovative siRNA formulations aimed at tackling heart-related ailments. The firm has initiated a clinical study for SRSD101 within the Chinese territory to address abnormal lipid levels, subsequent to receiving the nod from the regulatory body, the China National Medical Products Administration.

Dr. Qunsheng Ji, at the helm of Sirius Therapeutics, shared insights on the trial which leverages data from in vivo examinations showing an almost complete suppression of FXI concentrations that persisted up to half a year, following a one-time administration via the subcutaneous route, notably without any hemorrhagic complications. Dr. Ji underlined that the ongoing trial will scrutinize the distinctive treatment capacity of SRSD107 for these widely-encountered health concerns on a worldwide scale.

The initial phase trial of SRSD107, which is underway with the participation of healthy individuals in Australia, aims to discern the compound's safety profile, its ease of tolerance in humans, its pharmacokinetic attributes, and its pharmacodynamic influences, assessing both single-rising doses and escalating doses over time.

Cardiovascular events, like heart attacks, strokes rooted in an ischemic cause, and clotting in the veins, commonly stem from thrombosis. A global mortality research published by The Lancet reveals these thromboembolic complications are believed to lead to one out of every four deaths globally.

Sirius Therapeutics has developed the unique double-strand siRNA molecule, SRSD107, with a precise mechanism aimed at the gene expression of coagulation factor XI, diminishing the synthesis of the FXI protein which in turn inhibits the intrinsic pathway of blood coagulation and fosters anticoagulation and anti-thrombotic benefits. The design of SRSD107 aspires to extend its dosing interval, potentially up to once or twice annually.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of February 7, 2024, there are 38 investigational drugs for the F11 target, including 43 indications, 50 R&D institutions involved, with related clinical trials reaching 148, and as many as 4179 patents.

SRSD-107 targets the F11 gene and is intended for the treatment of cardiovascular diseases, specifically thrombosis, thromboembolism, and related conditions. While it has reached Phase 1 globally, it is currently at the IND application stage in China. Further research and clinical trials will be necessary to determine the drug's efficacy and safety in treating these cardiovascular disorders.

图形用户界面, 文本, 应用程序

描述已自动生成

Navigating Health Information: How to Use Synapse to Search for Mirtazapine
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Mirtazapine
9 February 2024
Mirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain.
Read →
Takeda and Protagonist Sign Global Deal for Experimental Blood Disorder Drug, Rusfertide
Latest Hotspot
3 min read
Takeda and Protagonist Sign Global Deal for Experimental Blood Disorder Drug, Rusfertide
9 February 2024
Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam
9 February 2024
Alprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway.
Read →
Jaguar Gene Therapy's JAG201 Trials Approved by FDA for Autism and Phelan-McDermid Syndrome Treatment
Latest Hotspot
3 min read
Jaguar Gene Therapy's JAG201 Trials Approved by FDA for Autism and Phelan-McDermid Syndrome Treatment
9 February 2024
Jaguar Gene Therapy has received the green light from the FDA to initiate trials on JAG201 targeting a specific genetic variant associated with Autism Spectrum Disorder and Phelan-McDermid Syndrome.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.